Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | THRB | P10828 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.49 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.49 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716102 | 0.93 | MAPT (0.57) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4712174 | 0.90 | MAPT (0.51) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4711636 | 0.88 | MEN1 (0.47) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4714667 | 0.86 | PLA2G10 (0.47) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| Phenylboronic Acid SCHEMBL6530013 | 0.86 | MAPT (0.51) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4715422 | 0.85 | MAPT (0.48) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4716291 | 0.85 | NOD2 (0.52) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4714198 | 0.85 | ALDH1A1 (0.45) | ALDH1A1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL4711774 | 0.84 | MAPT (0.51) | ALDH1A1L3MBTL1MAPTTDP1TSHR | |
| SCHEMBL4789540 | 0.79 | MAPT (0.49) | ALDH1A1L3MBTL1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | claimed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | claimed |
| US-7456286-B2 | Bicyclic heteroaromatic compounds as kinase inhibitors | UCB PHARMA, S.A. (BE) | 2008-11-25 | — | — | US | disclosed |
| EP-1549648-B1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2008-11-12 | — | — | EP | disclosed |
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | CELLTECH R&D LIMITED (GB) | 2006-06-08 | — | — | US | disclosed |
| EP-1549648-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | Celltech R & D Limited (GB) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004031188-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS | CELLTECH R & D LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122212-A1 | Bicyclic heteroaromatic compounds as kinase inhibitors | MAP2K2, MAP2K7, MAP2K3 | ALDH1A1 3407/4885L3MBTL1 2135/4885MEN1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.